VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.
Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.
CancerIQ’s technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers community-based providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and – most importantly – improve patient outcomes. Learn more about how CancerIQ is scaling the use of genetic testing to predict, preempt and prevent disease at canceriq.com.
Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.
Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.
Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.
PreciseDx is a company specializing in cancer risk stratification by providing patient-specific risk assessments through the analysis of morphological features. Utilizing artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that offer detailed insights into each patient's risk profile and potential outcomes, thereby enhancing treatment decision-making. The company combines its clinical, regulatory, and translational research expertise to advance technologies in areas such as clinical modeling, patient phenotyping, and image analysis, ultimately aiming to improve patient outcomes and quality of life in the realm of cancer and other diseases.
Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.
Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.
Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.
Antidote Technologies Ltd. operates as a digital health company. The company offers Antidote Match that helps patients to identify matching trials; Connect Network that streams the information to patients; and Antidote Bridge that allows adding details about studies to the available information. It serves medical researchers, pharmaceutical companies, and patient organizations. Antidote Technologies Ltd. was formerly known as TrialReach Ltd. and changed its name to Antidote Technologies Ltd. in September 2016. The company was founded in 2009 and is based in London, United Kingdom.
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.
VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.
Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.
Tasso, Inc. is a healthcare company based in Seattle, Washington, that specializes in the development of clinical-grade blood sample collection devices. Founded in 2012, Tasso has created innovative self-sampling devices that allow patients to collect their own blood at home with ease and convenience. These disposable devices are designed for user-friendliness, enabling individuals to obtain blood samples painlessly and securely. After collection, patients can mail the samples directly to qualified laboratories for analysis. Tasso's approach prioritizes patient comfort and privacy, fundamentally transforming the traditional blood collection process.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company focused on creating immunotherapies for various human diseases. Established in 2014 and headquartered in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts, the company utilizes advanced antibody science to develop large-scale production platforms for immunoglobulins. Its product pipeline includes SAB-142, which targets Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 aimed at Middle East Respiratory Syndrome Coronavirus (MERS-CoV). SAB Biotherapeutics is committed to addressing public health challenges, rare conditions, long-term diseases, and potential global pandemic threats through innovative therapeutic solutions.
Preventice Solutions, Inc. is a provider of healthcare solutions specializing in mobile health technologies and services. Founded in 2007 and based in Eagan, Minnesota, the company offers a range of platforms, including the PatientCare Portal for real-time patient data management, the PatientView Portal for healthcare organizations, and the PatientFlow Portal for monitoring centers. Preventice is known for its advanced wearable monitoring devices, such as the BodyGuardian Heart, which enhances patient mobility and compliance, and the BodyGuardian Verité, a dual-modality cardiac sensor. These technologies aim to facilitate the monitoring and management of patients with cardiac issues, improving health outcomes while potentially reducing the cost of care. The company was formed through the merger of Preventice Services and Preventice Technologies in 2014, and it operates additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.
Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.
Ayogo Health Inc. is a Vancouver-based company that specializes in developing games and applications aimed at managing chronic health conditions and enhancing patient adherence. Founded in 2008, Ayogo utilizes behavioral psychology and social gaming principles to improve health outcomes. Its flagship product, GoodLife, offers a customizable platform featuring gamification elements, incentives, and social interactions to engage users effectively. Additionally, Ayogo's Alternate Reality Games provide a suite of learning applications that blend online and real-world experiences. The company collaborates closely with patients, end-users, and clients, which include insurers, healthcare providers, and pharmaceutical companies. By focusing on psychosocial factors, Ayogo's platform enhances patient activation, adherence, and persistence in treatment, ultimately aiming to foster healthier patients and better financial outcomes for healthcare organizations.
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.
Private Equity Round in 2019
CIOX Health, LLC is a healthcare services company based in Alpharetta, Georgia, specializing in the management and exchange of health information. The firm operates a cloud-based platform that digitizes and organizes both structured and unstructured medical records, facilitating access to clinical data for various stakeholders, including healthcare providers, health plans, and government agencies. CIOX offers a range of services including information release, medical record retrieval, coding and education, and risk adjustment solutions. Their expertise is designed to improve patient outcomes while ensuring compliance with regulations regarding the release of medical information. CIOX Health serves a diverse clientele, including hospitals, physician practices, law firms, and life insurance companies, making it a key player in the healthcare information management sector. The company was established in 1976 and operates additional locations in Phoenix, Arizona, and Green Bay, Wisconsin.
ConnectedMed builds digital therapeutics platform that allows patients to manage their primary and chronic care needs.
TriNetX, Inc. is a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a platform that enables researchers to analyze patient populations and derive real-world evidence, thereby enhancing trial design and improving site selection. Key offerings include TriNetX Live, a cloud-based solution for real-time analytics; TriNetX Research, which delivers longitudinal clinical data; and TriNetX Download, a platform for accessing real-world clinical data. Additionally, TriNetX features Attract Trials for data alignment in collaboration, Natural Language Processing for extracting clinical insights from physician documentation, and specialized tools for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX also has offices in Sydney, London, and Sao Paulo, and maintains compliance with HIPAA and GDPR regulations.
Clinithink Ltd is a healthcare software company based in Bridgend, United Kingdom, that specializes in cloud-based data analytics solutions. Founded in 2009, the company has developed a platform known as CLiX, which employs Natural Language Processing (NLP) to convert unstructured clinical narratives into structured data. This technology allows healthcare providers, pharmaceutical companies, and content vendors to collect and analyze clinical trial data effectively. Clinithink's products include CLiX ENRICH, which facilitates the indexing and recording of clinical trial data in a preferred narrative format, and CLiX RARE, aimed at diagnosing genetic disorders in newborns. Through its innovative approach, Clinithink supports healthcare applications in data analytics, coding, and decision-making.
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence
ClearDATA Networks, Inc. specializes in healthcare cloud computing and information security solutions, catering to healthcare providers, life sciences organizations, and payers. Founded in 2009 and headquartered in Austin, Texas, with additional offices in San Francisco and Scottsdale, the company offers a multi-cloud platform that automates, protects, and manages healthcare applications and data. Key offerings include ClearDATA Comply, which helps organizations ensure cloud compliance with privacy regulations; ClearDATA Assess, designed for conducting mandatory HIPAA Security Risk Assessments; and ClearDATA Locate Mask, which enables healthcare organizations to utilize sensitive data safely by masking personal information. ClearDATA's HITRUST-certified cloud is recognized for its robust security and compliance solutions, providing a comprehensive Business Associate Agreement (BAA) and enabling clients to improve data management while minimizing privacy risks. The company's services extend to process design, solution architecture, custom development, and security risk assessments, empowering the healthcare sector to enhance service delivery through advanced analytics and scalable IT infrastructure.
Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.
Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.
Prognos Health is a prominent health tech company specializing in healthcare analytics aimed at improving disease management and treatment decision-making. Its platform, prognosFACTOR, allows users to quickly query billions of lab and health records from over 325 million de-identified patients, significantly reducing the time needed to answer critical healthcare questions. The Prognos Registry serves as the largest source of clinical diagnostics information across more than 30 disease areas, encompassing over 5 billion medical records for 100 million patients. By employing a suite of 500 proprietary clinical algorithms, Prognos facilitates earlier patient identification, enhancing treatment decisions and risk management. The company collaborates with key stakeholders in the healthcare ecosystem, including pharmaceutical manufacturers and payers, providing HIPAA-compliant patient-centric data through the Prognos Marketplace for various applications such as cohort design and health outcomes analysis.
Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.
Antidote Technologies Ltd. operates as a digital health company. The company offers Antidote Match that helps patients to identify matching trials; Connect Network that streams the information to patients; and Antidote Bridge that allows adding details about studies to the available information. It serves medical researchers, pharmaceutical companies, and patient organizations. Antidote Technologies Ltd. was formerly known as TrialReach Ltd. and changed its name to Antidote Technologies Ltd. in September 2016. The company was founded in 2009 and is based in London, United Kingdom.
Serimmune Inc. is a biotechnology company focused on developing diagnostics and therapeutics for autoimmune diseases. Founded in 2014 and based in Goleta, California, the company utilizes its serum epitope repertoire analysis (SERA) technology platform, which integrates bacterial display peptide libraries, sequencing, machine learning, and bioinformatics. This platform enables the mapping of distinct antibodies within an immune repertoire to specific antigens linked to infections, allergens, microbiome organisms, autoimmune diseases, and cancers. By providing insights into the immune response, Serimmune aims to facilitate the creation of new diagnostics, vaccines, and therapeutics, thereby enhancing the ability of medical practitioners to address various health challenges.
ClearDATA Networks, Inc. specializes in healthcare cloud computing and information security solutions, catering to healthcare providers, life sciences organizations, and payers. Founded in 2009 and headquartered in Austin, Texas, with additional offices in San Francisco and Scottsdale, the company offers a multi-cloud platform that automates, protects, and manages healthcare applications and data. Key offerings include ClearDATA Comply, which helps organizations ensure cloud compliance with privacy regulations; ClearDATA Assess, designed for conducting mandatory HIPAA Security Risk Assessments; and ClearDATA Locate Mask, which enables healthcare organizations to utilize sensitive data safely by masking personal information. ClearDATA's HITRUST-certified cloud is recognized for its robust security and compliance solutions, providing a comprehensive Business Associate Agreement (BAA) and enabling clients to improve data management while minimizing privacy risks. The company's services extend to process design, solution architecture, custom development, and security risk assessments, empowering the healthcare sector to enhance service delivery through advanced analytics and scalable IT infrastructure.
Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.
Arcadia Solutions, LLC specializes in electronic health record (EHR) data aggregation and analytics for the healthcare industry. Founded in 2002 and based in Burlington, Massachusetts, the company delivers a range of services and proprietary software to large healthcare providers, payors, accountable care organizations, and health information exchanges. Arcadia focuses on integrating data from over 30 EHR platforms and enhances it with claims and operational data to improve patient care quality, practice efficiency, and financial performance. The company offers IT services tailored for accountable care organizations, consulting services, EHR implementation and optimization, health systems performance management, and information security. Additionally, Arcadia provides a customizable suite of solutions for managing health IT infrastructures and technology systems, including a service desk, performance monitoring, and hardware lifecycle management. Its clients include hospitals, large health systems, independent practice associations, and community health centers across the nation.
StayWell Company is a health engagement firm that specializes in patient education and population health management services. It serves a diverse range of clients, including businesses, government entities, and healthcare associations. By leveraging extensive experience in the healthcare sector, StayWell designs customizable solutions that facilitate health engagement and foster behavior change. The company offers a comprehensive portfolio of services that includes health information dissemination, educational programs, and marketing engagement strategies. StayWell's approach is data-driven, ensuring that each phase of program development—from design to implementation and performance evaluation—reflects measurable outcomes. As a result, clients benefit from reduced health costs, increased participation rates, enhanced patient acquisition, improved health outcomes, and high levels of program satisfaction.
OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, that specializes in developing molecular diagnostics and informatics aimed at combating infectious diseases. The company offers a range of products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and antimicrobial resistance markers, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to help manage multidrug-resistant organisms in healthcare settings. Through its strategic collaboration with the New York State Department of Health, OpGen is working on solutions to detect and manage antimicrobial-resistant infections in healthcare facilities. The company's innovative technologies are utilized by academic, government, and research institutions globally for applications such as strain typing and genome assembly. OpGen aims to enhance patient care and outcomes while addressing the growing challenge of antibiotic resistance.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.
GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.
WellDoc, Inc. is a digital health company focused on chronic disease management, particularly diabetes care. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc offers innovative solutions such as the DiabetesManager platform and BlueStar mobile prescription therapy. The DiabetesManager platform facilitates patient-provider coordination through features like personalized coaching, medication reminders, and real-time alerts, while BlueStar offers patients immediate guidance to enhance self-management of diabetes. WellDoc’s services also include clinical decision support for healthcare professionals and a comprehensive suite of technical services, such as software development and regulatory management. The company aims to improve health outcomes and reduce healthcare costs by integrating behavioral and motivational applications with everyday technology. WellDoc serves a diverse range of clients, including payors, employers, pharmaceutical and medical device companies, and healthcare providers.
OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, that specializes in developing molecular diagnostics and informatics aimed at combating infectious diseases. The company offers a range of products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and antimicrobial resistance markers, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to help manage multidrug-resistant organisms in healthcare settings. Through its strategic collaboration with the New York State Department of Health, OpGen is working on solutions to detect and manage antimicrobial-resistant infections in healthcare facilities. The company's innovative technologies are utilized by academic, government, and research institutions globally for applications such as strain typing and genome assembly. OpGen aims to enhance patient care and outcomes while addressing the growing challenge of antibiotic resistance.
ClearDATA Networks, Inc. specializes in healthcare cloud computing and information security solutions, catering to healthcare providers, life sciences organizations, and payers. Founded in 2009 and headquartered in Austin, Texas, with additional offices in San Francisco and Scottsdale, the company offers a multi-cloud platform that automates, protects, and manages healthcare applications and data. Key offerings include ClearDATA Comply, which helps organizations ensure cloud compliance with privacy regulations; ClearDATA Assess, designed for conducting mandatory HIPAA Security Risk Assessments; and ClearDATA Locate Mask, which enables healthcare organizations to utilize sensitive data safely by masking personal information. ClearDATA's HITRUST-certified cloud is recognized for its robust security and compliance solutions, providing a comprehensive Business Associate Agreement (BAA) and enabling clients to improve data management while minimizing privacy risks. The company's services extend to process design, solution architecture, custom development, and security risk assessments, empowering the healthcare sector to enhance service delivery through advanced analytics and scalable IT infrastructure.
Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.
Ayogo Health Inc. is a Vancouver-based company that specializes in developing games and applications aimed at managing chronic health conditions and enhancing patient adherence. Founded in 2008, Ayogo utilizes behavioral psychology and social gaming principles to improve health outcomes. Its flagship product, GoodLife, offers a customizable platform featuring gamification elements, incentives, and social interactions to engage users effectively. Additionally, Ayogo's Alternate Reality Games provide a suite of learning applications that blend online and real-world experiences. The company collaborates closely with patients, end-users, and clients, which include insurers, healthcare providers, and pharmaceutical companies. By focusing on psychosocial factors, Ayogo's platform enhances patient activation, adherence, and persistence in treatment, ultimately aiming to foster healthier patients and better financial outcomes for healthcare organizations.
Daktari Diagnostics, Inc., a healthcare solutions company, develops and provides portable point-of-care diagnostic platforms for disease management Worldwide. It offers Daktari Virology, a platform for HCV and HIV detection; Daktari InSight, a data management service that connects Daktari’s systems to its customers; and Daktari Sickle Cell, a solution that provides tests to identify infants with sickle cell disease from a drop of blood. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
WiserTogether’s personalized healthcare treatment comparison software enables consumers to choose the right treatment – most effective in the outcome, most personally suitable, and most cost-effective and affordable. The result is improved health and improved costs for consumers, their employers, payers, and providers. The company serves over 3 million people through their employers and health plans.
It was founded in 2008 and is based in Washington, District of Columbia.
Preventice Inc. develops mobile health applications and patient monitoring systems that connect mobile, home-based, and on-premise technologies for continuous patient care. It offers HealthClips Rx, an interactive patient education platform that feeds data about patient compliance and post-surgical complications back into the clinical system; and CARD-Contact Allergen Replacement Database, which provides people with skin allergies access to information about products that contain known allergens. The company also provides Coppertone MyUVAlert that helps people avoid overexposure to the sun; and iManage Migraine, an application that helps people to track and understand what triggers their migraine headaches. In addition, it offers care plan management, patient education, remote monitoring, relationship management, and integrated analytics solutions. Preventice Inc. was formerly known as Boost Information Systems, Inc. The company was founded in 2007 and is based in Rochester, Minnesota with additional offices in Fargo, North Dakota.
Healthsense, Inc. specializes in remote monitoring services aimed at the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company provides health and safety monitoring solutions that track essential daily activities such as eating, sleeping, and movement. Their technology includes analytics that transform data into actionable insights, a centralized dashboard for caregivers, health notes to alert changes in behavior, and real-time notifications for urgent needs. These features help caregivers respond effectively to the needs of seniors, enhancing their independence and overall quality of life. Healthsense serves various markets, including senior living, managed care, and home care, and operates as a subsidiary of GreatCall, Inc. since December 2016.
Cleveland HeartLab, Inc. is a clinical reference laboratory dedicated to the prevention of cardiovascular disease (CVD) through innovative biomarker technologies and proprietary diagnostic tests. The company specializes in the early identification of individuals at risk for CVD, emphasizing the management and reduction of inflammation. Cleveland HeartLab provides a range of clinical laboratory services, including an inflammatory panel for CVD, an advanced CVD risk profile, and lipid testing. By focusing on novel molecular biomarkers, the company aims to enhance disease management and improve patient outcomes in cardiovascular health.
Idenix Pharmaceuticals is a biopharmaceutical company focused on discovering and developing drugs for the treatment of viral diseases, primarily targeting hepatitis C virus (HCV). With operations in the United States and Europe, the company's research efforts have led to significant advancements in HCV treatment, including the completion of a proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. Idenix has also initiated a phase IIa clinical trial to evaluate its lead drug candidate, IDX184, in combination with existing therapies. In addition to HCV, Idenix is developing products and candidates aimed at treating hepatitis B virus (HBV), human immunodeficiency virus type I (HIV), and acquired immune deficiency syndrome (AIDS).
AdvanDx, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in molecular diagnostic tests for identifying pathogens responsible for critical infections in hospitalized patients. Founded in 2002, the company focuses on improving patient outcomes by facilitating earlier antibiotic therapy through rapid pathogen identification. AdvanDx offers a range of products, including QuickFISH and PNA FISH tests for detecting bacteria and yeast from positive blood cultures, as well as XpressFISH for identifying resistance markers. Its PNA Probes target ribosomal RNA sequences in bacteria and fungi. The company provides its diagnostic solutions to medical centers, reference laboratories, government institutions, and community hospitals, distributing its products through a network of sales representatives and international distributors. AdvanDx has operated as a subsidiary of OpGen, Inc. since 2015.
WellDoc, Inc. is a digital health company focused on chronic disease management, particularly diabetes care. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc offers innovative solutions such as the DiabetesManager platform and BlueStar mobile prescription therapy. The DiabetesManager platform facilitates patient-provider coordination through features like personalized coaching, medication reminders, and real-time alerts, while BlueStar offers patients immediate guidance to enhance self-management of diabetes. WellDoc’s services also include clinical decision support for healthcare professionals and a comprehensive suite of technical services, such as software development and regulatory management. The company aims to improve health outcomes and reduce healthcare costs by integrating behavioral and motivational applications with everyday technology. WellDoc serves a diverse range of clients, including payors, employers, pharmaceutical and medical device companies, and healthcare providers.
ClearDATA Networks, Inc. specializes in healthcare cloud computing and information security solutions, catering to healthcare providers, life sciences organizations, and payers. Founded in 2009 and headquartered in Austin, Texas, with additional offices in San Francisco and Scottsdale, the company offers a multi-cloud platform that automates, protects, and manages healthcare applications and data. Key offerings include ClearDATA Comply, which helps organizations ensure cloud compliance with privacy regulations; ClearDATA Assess, designed for conducting mandatory HIPAA Security Risk Assessments; and ClearDATA Locate Mask, which enables healthcare organizations to utilize sensitive data safely by masking personal information. ClearDATA's HITRUST-certified cloud is recognized for its robust security and compliance solutions, providing a comprehensive Business Associate Agreement (BAA) and enabling clients to improve data management while minimizing privacy risks. The company's services extend to process design, solution architecture, custom development, and security risk assessments, empowering the healthcare sector to enhance service delivery through advanced analytics and scalable IT infrastructure.
GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Humedica is the clinical intelligence company that powers health care providers and life sciences organ izations to make better-informed, more confident decisions by transforming unconnected data from multiple sources into real-world insights.
Prognos Health is a prominent health tech company specializing in healthcare analytics aimed at improving disease management and treatment decision-making. Its platform, prognosFACTOR, allows users to quickly query billions of lab and health records from over 325 million de-identified patients, significantly reducing the time needed to answer critical healthcare questions. The Prognos Registry serves as the largest source of clinical diagnostics information across more than 30 disease areas, encompassing over 5 billion medical records for 100 million patients. By employing a suite of 500 proprietary clinical algorithms, Prognos facilitates earlier patient identification, enhancing treatment decisions and risk management. The company collaborates with key stakeholders in the healthcare ecosystem, including pharmaceutical manufacturers and payers, providing HIPAA-compliant patient-centric data through the Prognos Marketplace for various applications such as cohort design and health outcomes analysis.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
eHealth Technologies™ (formerly eHealth Global) is a healthcare digital services company focused on retrieving, digitizing, storing, securing, and providing access to patient medical records. eHealth Technologies™ utilizes a processes to retrieve, secure, store, transmit, and present patient data to healthcare providers.
Healthsense, Inc. specializes in remote monitoring services aimed at the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company provides health and safety monitoring solutions that track essential daily activities such as eating, sleeping, and movement. Their technology includes analytics that transform data into actionable insights, a centralized dashboard for caregivers, health notes to alert changes in behavior, and real-time notifications for urgent needs. These features help caregivers respond effectively to the needs of seniors, enhancing their independence and overall quality of life. Healthsense serves various markets, including senior living, managed care, and home care, and operates as a subsidiary of GreatCall, Inc. since December 2016.
Remedy Informatics, formerly known as RemedyMD, is a prominent provider of patient registries and medical research software designed to enhance the efficiency of translational medicine. The company specializes in developing meta-registries and clinical informatics systems that aid scientific researchers by utilizing predictive informatics to identify patterns, personalize treatment, and integrate diverse data types. Built on the Mosaic™ Platform, Remedy's offerings are highly configurable, supporting various healthcare and life science research initiatives. The company's mission focuses on significantly improving the effectiveness of research, aiming to yield tangible outcomes in healthcare advancements globally.
Healthsense, Inc. specializes in remote monitoring services aimed at the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company provides health and safety monitoring solutions that track essential daily activities such as eating, sleeping, and movement. Their technology includes analytics that transform data into actionable insights, a centralized dashboard for caregivers, health notes to alert changes in behavior, and real-time notifications for urgent needs. These features help caregivers respond effectively to the needs of seniors, enhancing their independence and overall quality of life. Healthsense serves various markets, including senior living, managed care, and home care, and operates as a subsidiary of GreatCall, Inc. since December 2016.
Rock Health is a venture capital firm based in San Francisco, California, that specializes in investing in early-stage digital health startups. Founded in 2010, the firm focuses on supporting entrepreneurs who are developing innovative solutions at the intersection of healthcare and technology. It provides funding, access to a network of venture and corporate partners, legal support, and office space to its portfolio companies. Rock Health aims to invest in companies that create health-oriented products, such as activity-tracking devices, telemedicine applications, and data analytics tools that improve healthcare outcomes and reduce costs. Its notable portfolio includes startups like Omada Health, Collective Health, and Doctor on Demand, which are dedicated to enhancing healthcare accessibility and effectiveness. The firm typically considers investments ranging from $0.1 to $0.25 million per company.
Mihealth Global Systems, Inc. is a Toronto-based company that develops a healthcare messaging system designed to facilitate bi-directional communication between patients and physicians. Founded in 2009 by Dr. Wendy Graham, the mihealth application provides patients with secure online access to their physician-validated health information, enabling them to manage and organize their health data effectively. This interactive mobile technology enhances communication and allows physicians to stay updated on their patients' medical histories. By simplifying the connection between patients and healthcare providers, mihealth empowers individuals to take control of their health and wellness through accessible and user-friendly tools available on smartphones and tablets.
Aptus Health provides digital health engagement solutions for healthcare providers and patients. Aptus Health is on a mission to dynamically connect health and life sciences companies with healthcare professionals, healthcare consumers, and other members of the healthcare ecosystem.
Daktari Diagnostics, Inc., a healthcare solutions company, develops and provides portable point-of-care diagnostic platforms for disease management Worldwide. It offers Daktari Virology, a platform for HCV and HIV detection; Daktari InSight, a data management service that connects Daktari’s systems to its customers; and Daktari Sickle Cell, a solution that provides tests to identify infants with sickle cell disease from a drop of blood. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.
Preventice Inc. develops mobile health applications and patient monitoring systems that connect mobile, home-based, and on-premise technologies for continuous patient care. It offers HealthClips Rx, an interactive patient education platform that feeds data about patient compliance and post-surgical complications back into the clinical system; and CARD-Contact Allergen Replacement Database, which provides people with skin allergies access to information about products that contain known allergens. The company also provides Coppertone MyUVAlert that helps people avoid overexposure to the sun; and iManage Migraine, an application that helps people to track and understand what triggers their migraine headaches. In addition, it offers care plan management, patient education, remote monitoring, relationship management, and integrated analytics solutions. Preventice Inc. was formerly known as Boost Information Systems, Inc. The company was founded in 2007 and is based in Rochester, Minnesota with additional offices in Fargo, North Dakota.
HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.
PHT Corporation is a leading provider of electronic patient-reported outcome (ePRO) solutions utilized in clinical trials globally. The company offers the LogPad and StudyPad Systems, which enhance data quality and facilitate efficient data collection. Additionally, PHT's StudyWorks online portal grants study sponsors, monitors, and sites real-time access to trial data, enabling informed decision-making. By leveraging these technologies, biopharmaceutical and medical device companies can obtain more comprehensive data and accelerate their trial processes, ultimately contributing to the success of clinical studies.
VisEn Medical, Inc. specializes in the design, development, and commercialization of fluorescence in vivo imaging technology platforms. The company focuses on its Fluorescence Molecular Tomographic (FMT) imaging systems and various vivo imaging agents that enhance the identification, characterization, and quantification of disease biomarkers and therapeutic efficacy in living organisms. Among its notable products are ReninSense680, an imaging agent used for monitoring hypertension and renal disease biomarkers, and VivoTagR 680 XL, a fluorescent dye suitable for labeling biomolecules in diverse in vitro and in vivo imaging applications. Additionally, VisEn Medical provides advanced fluorescence tomographic imaging systems to support its imaging technology offerings.
HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.
Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, specializing in patient management solutions for oncology and genetic disorders. Founded in 2005, Asuragen focuses on the development and commercialization of diagnostic products for clinical laboratories and pharmaceutical partners. Its product portfolio includes a variety of assays for cancer detection and genetic testing, such as the AmplideX FMR1 PCR reagents for fragile X syndrome and the Signature® line of tests for various cancer mutations. The company utilizes patented technologies, including Armored RNA®, to enhance the accuracy and reliability of its diagnostics. Additionally, Asuragen provides testing services and operates a cGMP manufacturing facility, enabling a comprehensive approach to molecular oncology that encompasses discovery, testing, production, and commercialization. Asuragen's commitment to innovation aids the medical community in improving treatment outcomes through precise diagnostic solutions.
PHT Corporation is a leading provider of electronic patient-reported outcome (ePRO) solutions utilized in clinical trials globally. The company offers the LogPad and StudyPad Systems, which enhance data quality and facilitate efficient data collection. Additionally, PHT's StudyWorks online portal grants study sponsors, monitors, and sites real-time access to trial data, enabling informed decision-making. By leveraging these technologies, biopharmaceutical and medical device companies can obtain more comprehensive data and accelerate their trial processes, ultimately contributing to the success of clinical studies.
PHT Corporation is a leading provider of electronic patient-reported outcome (ePRO) solutions utilized in clinical trials globally. The company offers the LogPad and StudyPad Systems, which enhance data quality and facilitate efficient data collection. Additionally, PHT's StudyWorks online portal grants study sponsors, monitors, and sites real-time access to trial data, enabling informed decision-making. By leveraging these technologies, biopharmaceutical and medical device companies can obtain more comprehensive data and accelerate their trial processes, ultimately contributing to the success of clinical studies.